Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease

Drugs
Young-A Heo, Lesley J Scott

Abstract

Oral deutetrabenazine (Austedo™), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms associated with Huntington's disease (HD). In the pivotal 12-week phase III FIRST-HD trial (n = 90), deutetrabenazine, at doses titrated for optimal chorea control and tolerability (maintenance dosage range 12-48 mg/day), was significantly more effective for controlling chorea in HD patients than placebo. In the ongoing phase III ARC-HD trial, a preliminary analysis demonstrated that deutetrabenazine treatment was associated with improvements in chorea control at 54 weeks in patients who had completed FIRST-HD (i.e. ≤ 66 weeks' treatment; rollover cohort) or switched overnight from tetrabenazine to deutetrabenazine. The tolerability profile of deutetrabenazine is similar to that of placebo, with most treatment-emergent adverse events of mild or moderate severity. In both trials, with the exception of somnolence, individual neuropsychiatric adverse events typically occurred in < 7% of deutetrabenazine recipients; in FIRST-HD, there was no significant difference in the incidence of individual neuropsychiatric events between the deu...Continue Reading

References

May 16, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Ralf Reilmann
Jul 30, 2014·Expert Opinion on Therapeutic Patents·Graham S Timmins
Aug 27, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph Jankovic, Raymund A C Roos
Jul 6, 2016·JAMA : the Journal of the American Medical Association·Michael D Geschwind, Nick Paras
Jul 6, 2016·JAMA : the Journal of the American Medical Association·UNKNOWN Huntington Study GroupEmily Christopher
Dec 19, 2016·Drugs·Emma M Coppen, Raymund A C Roos
Mar 8, 2017·Journal of Clinical Movement Disorders·Daniel O ClaassenDavid Stamler
Mar 23, 2017·Current Neurology and Neuroscience Reports·Kara J WyantPraveen Dayalu
Jul 12, 2017·JAMA Neurology·Samuel FrankUNKNOWN Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators
Sep 19, 2017·Movement Disorders Clinical Practice·Filipe B RodriguesEdward J Wild

❮ Previous
Next ❯

Citations

Jul 12, 2018·Expert Review of Neurotherapeutics·Hassaan Bashir, Joseph Jankovic
Jan 10, 2019·Neurodegenerative Disease Management·Alby Richard, Samuel Frank
Jul 11, 2021·Bioorganic & Medicinal Chemistry Letters·Shaoyi Sun, Steven S Wesolowski
Apr 3, 2019·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Feb 26, 2020·Journal of Medicinal Chemistry·Matthew A CernyGregory S Walker
Aug 24, 2021·Frontiers in Cellular Neuroscience·Xiaoyu Dong, Shuyan Cong

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.